Therapy Developed That May Inhibit Kidney Disorder by Differentiating Disease Processes and Biomarkers
By LabMedica International staff writers Posted on 06 Aug 2013 |
Image: A kit used to collect exhaled breath for metabolic analysis in a study of methylmalonic academia (MMA) (Photo courtesy of Maggie Bartlett, NHGRI; NIH Clinical Center, Bethesda, MD, USA).
A group of investigators has overcome a major biologic obstacle in an effort to find enhanced treatments for patients with a rare disease called methylmalonic acidemia (MMA). The scientists, utilizing genetically engineered mice, identified a series of biomarkers of kidney damage—a key characteristic of the disorder—and demonstrated that antioxidant therapy protected kidney function in the mice.
Researchers from the US National Human Genome Research Institute (NHGRI; Bethesda, MD, USA), part of the National Institutes of Health (NIH), substantiated the same biomarkers in 46 patients with MMA seen at the NIH Clinical Center. The biomarkers offer new tools for monitoring disease progression and the effects of therapies, both of which will be helpful in the researchers' design of clinical trials for this disease.
The discovery, reported in the July 29, 2013, advance online issue of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS), creates the possibility for use of antioxidant therapy in a clinical trial for patients with MMA. It also demonstrates the processes by which mitochondrial dysfunction affects kidney disease. Mitochondrial dysfunction is a problem not only in rare disorders, such as MMA, but also in a broad range of common disorders, such as diabetes, obesity, and cancer.
Related Links:
National Human Genome Research Institute
Researchers from the US National Human Genome Research Institute (NHGRI; Bethesda, MD, USA), part of the National Institutes of Health (NIH), substantiated the same biomarkers in 46 patients with MMA seen at the NIH Clinical Center. The biomarkers offer new tools for monitoring disease progression and the effects of therapies, both of which will be helpful in the researchers' design of clinical trials for this disease.
The discovery, reported in the July 29, 2013, advance online issue of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS), creates the possibility for use of antioxidant therapy in a clinical trial for patients with MMA. It also demonstrates the processes by which mitochondrial dysfunction affects kidney disease. Mitochondrial dysfunction is a problem not only in rare disorders, such as MMA, but also in a broad range of common disorders, such as diabetes, obesity, and cancer.
Related Links:
National Human Genome Research Institute
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples